Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$409K Sell
3,458
-319
-8% -$36.8K 0.02% 248
2026
Q1
$451K Buy
3,777
+155
+4% +$20.3K 0.02% 230
2025
Q4
$493K Sell
3,622
-28
-0.8% -$4.03K 0.02% 222
2025
Q3
$538K Sell
3,650
-439
-11% -$60.9K 0.02% 213
2025
Q2
$529K Sell
4,089
-87
-2% -$10.5K 0.03% 177
2025
Q1
$499K Buy
4,176
+111
+3% +$13.8K 0.03% 178
2024
Q4
$472K Buy
4,065
+1,393
+52% +$176K 0.02% 190
2024
Q3
$361K Buy
+2,672
New +$357K 0.02% 220

Other funds holding XYL

Rockland Trust's XYL Position: Q2 2026 in Review

Rockland Trust reduced its Xylem (XYL) stake by 8.4% in Q2 2026, selling an estimated $36.8K and leaving 3,458 shares worth $409K. The position accounts for 0.02% of the portfolio, ranked #248.

Rockland Trust first reported a position in XYL in Q3 2024 and has held it in 8 quarters since. The position peaked at $538K in Q3 2025. 456 funds tracked by Wall St. Rank hold XYL as of Q2 2026.

  • Rockland Trust held 3,458 shares of Xylem worth $409K as of Q2 2026.
  • Rockland Trust sold 319 Xylem shares in Q2 2026, an estimated $36.8K.
  • Xylem made up 0.02% of Rockland Trust's portfolio in Q2 2026, its #248 holding.
  • Rockland Trust first reported a position in Xylem in Q3 2024 and has held it in 8 quarters since.
  • Rockland Trust's Xylem position peaked at $538K in Q3 2025.
  • 456 funds tracked by Wall St. Rank held Xylem as of Q2 2026.

Based on Rockland Trust's 13F filing for Q2 2026, filed 8 Jul 2026.